Journal of clinical tuberculosis and other mycobacterial diseases · 2021
Variances in BCG protection against COVID-19 mortality: A global assessment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sarfraz Zouina, Sarfraz Azza, Pandav Krunal, Singh Makkar Sarabjot, Hasan Siddiqui Saman, Patel Gaurav, Platero-Portillo Tania, Singh Bishnu Mohan, Maideen Mohamed Iburahim Haja, Sarvepalli Deepika, Sarfraz Muzna, Cardona-Guzman Jose, Sanchez-Gonzalez Marcos A, Cherrez-Ojeda Ivan
Аннотация
The BCG vaccine is known to impart nonspecific immunological benefits alongside conferring protection to tuberculosis in endemic regions. It is also known to protect against bladder cancer and other respiratory tract infections. During the coronavirus disease 2019 (COVID-19) pandemic, the BCG vaccine has gained attention due to its role in conferring protective immunity. We demonstrate the potential immunological protective mechanisms that play a role against COVID-19. We conduct a global assessment of the countries that have the highest and lowest mortality rates determined by an a priori methodology. Lastly, we discuss the potential limitations of incorporating BCG vaccines as potential strategies against COVID-19 and provide recommendations regarding their use in ongoing and future epidemics.